Allied Market Research

2025

Wet Age-related Macular Degeneration (amd) Drugs Market

Wet Age-Related Macular Degeneration (AMD) Drugs Market, by Type (LUCENTIS, AVASTIN, EYLEA, OTHER DRUGS) and, by END USER (HOSPITALS, OPHTHALMIC CLINICS, RESEARCH INSTITUTES, CONTRACT RESEARCH ORGANIZATIONS): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

  • Jun 2025

  • Pages: NA

  • Tables: NA

  • Charts: NA

Select an option
Cloud Access (30% Off) $3,690 $2,583
Business User License (30% Off) $5,820 $4,074
Enterprise License (30% Off) $9,870 $6,909
Library Membership (15% Off) $1,175 $999
Enquiry Now
Author's: | Roshan Deshmukh
Publish Date:
Enquire Before Buying Customization Request Speak with Analyst

Get Sample to Email

  Wet Age-Related Macular Degeneration Report Highlights

Aspects Details
icon_5
By Type
  • LUCENTIS
  • AVASTIN
  • EYLEA
  • OTHER DRUGS
icon_6
By END USER
  • HOSPITALS
  • OPHTHALMIC CLINICS
  • RESEARCH INSTITUTES
  • CONTRACT RESEARCH ORGANIZATIONS
icon_7
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
icon_8
Key Market Players

Novartis AG, Regeneron Pharmaceuticals Inc., Ophthotech Corporation, Pfizer Inc., Roche Holding AG, Sanofi, Genentech Inc., Bayer AG, Allergan plc, Santen Pharmaceutical Co. Ltd.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?
*Terms and Conditions Apply

Wet Age-Related Macular Degeneration

Global Opportunity Analysis and Industry Forecast, 2023-2032

help@alliedmarketresearch.com